Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Oxford Nanopore Technologies's accounts receivables for the quarter that ended in Dec. 2025 was $62.2 Mil.
Accounts receivable can be measured by Days Sales Outstanding.
Oxford Nanopore Technologies's Days Sales Outstanding for the quarter that ended in Dec. 2025 was 71.73.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Oxford Nanopore Technologies's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was $0.95.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Oxford Nanopore Technologies's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Oxford Nanopore Technologies's accounts receivable are only considered to be worth 75% of book value:
Oxford Nanopore Technologies's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Oxford Nanopore Technologies Accounts Receivable Related Terms
Oxford Nanopore Technologies Accounts Receivable Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Accounts Receivable of $62.2 Mil mean?
Oxford Nanopore Technologies (OXFYY) has a Accounts Receivable of $62.2 Mil as of Dec. 2025. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Oxford Nanopore Technologies and its competitors.
Is Oxford Nanopore Technologies' Accounts Receivable too high?
Oxford Nanopore Technologies' current Accounts Receivable is $62.2 Mil. Overall, Oxford Nanopore Technologies has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxford Nanopore Technologies' Accounts Receivable compare to VRTX and REGN?
Oxford Nanopore Technologies' Accounts Receivable of $62.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Biotechnology company?
A good Accounts Receivable depends on the Biotechnology industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Oxford Nanopore Technologies and its competitors. Oxford Nanopore Technologies's current Accounts Receivable is $62.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford Nanopore Technologies stock overvalued right now?
Based on GuruFocus' analysis, Oxford Nanopore Technologies (OXFYY) is currently considered Significantly Undervalued. The stock's GF Value™ is $10.42, compared to a current price of $6.05 — trading 41.9% below its estimated fair value. The current Accounts Receivable is $62.2 Mil. Oxford Nanopore Technologies' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Oxford Nanopore Technologies (OXFYY), the current Accounts Receivable is $62.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford Nanopore Technologies (OXFYY) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford Nanopore Technologies stock appears to be undervalued.
The current stock price of $6.05 is trading 41.9% below its estimated GF Value™ of $10.42.
GuruFocus considers Oxford Nanopore Technologies to be Significantly Undervalued.
Key valuation signals for OXFYY:
Accounts Receivable: $62.2 Mil
GF Value™: $10.42 vs. price of $6.05 (41.9% below fair value)
No single metric tells the full story. See the OXFYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC.
50GF Score
Get the complete analysis for OXFYY
Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXFYY has been successfully added to your 
